Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$41.95M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
1777.3%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$69.36M
Q3 2024
Cash
Q3 2024
P/E
-0.8143
Nov 29, 2024 EST
Free Cash Flow
-$12.18M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019
Selling, General & Admin $14.90M $15.83M $8.451M $1.800M $544.0K
YoY Change -5.86% 87.34% 369.5% 230.88%
% of Gross Profit
Research & Development $25.43M $78.72M $23.60M $15.48M $5.338M
YoY Change -67.69% 233.62% 52.46% 189.92%
% of Gross Profit
Depreciation & Amortization $39.00K $27.00K $18.00K $15.00K $0.00
YoY Change 44.44% 50.0% 20.0%
% of Gross Profit
Operating Expenses $45.45M $94.55M $32.05M $17.28M $5.882M
YoY Change -51.93% 195.04% 85.49% 193.71%
Operating Profit -$45.45M -$94.55M -$32.05M -$17.28M
YoY Change -51.93% 195.04% 85.49%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019
Interest Expense -$4.200M -$1.500M
YoY Change 180.0%
% of Operating Profit
Other Income/Expense, Net -$229.0K -$506.0K $7.000K $11.00K $0.00
YoY Change -54.74% -7328.57% -36.36%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019
Pretax Income -$45.67M -$95.06M -$32.04M -$17.27M -$5.882M
YoY Change -51.95% 196.69% 85.57% 193.52%
Income Tax $30.00K $25.00K $0.00 $0.00
% Of Pretax Income
Net Earnings -$45.70M -$95.08M -$32.04M -$17.27M -$5.882M
YoY Change -51.93% 196.76% 85.57% 193.52%
Net Earnings / Revenue
Basic Earnings Per Share -$1.34 -$4.09 -$2.64 -$21.80
Diluted Earnings Per Share -$1.34 -$4.09 -$2.64 -$21.80 -$258.1K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019
Cash & Short-Term Investments $83.11M $90.28M $146.3M $79.40M $1.740M
YoY Change -7.95% -38.28% 84.24% 4463.22%
Cash & Equivalents $49.26M $45.92M $146.3M $79.40M $1.740M
Short-Term Investments $33.85M $44.36M
Other Short-Term Assets $4.857M $2.697M $3.140M $1.386M $174.0K
YoY Change 80.09% -14.11% 126.55% 696.55%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $87.96M $92.98M $149.4M $80.79M $1.914M
YoY Change -5.39% -37.78% 84.96% 4120.79%
Property, Plant & Equipment $59.00K $98.00K $38.00K $56.00K $0.00
YoY Change -39.8% 157.89% -32.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.068M $1.086M $32.00K $65.00K $0.00
YoY Change -1.66% 3293.75% -50.77%
Total Long-Term Assets $1.127M $1.184M $70.00K $121.0K $0.00
YoY Change -4.81% 1591.43% -42.15%
Total Assets $89.09M $94.16M $149.5M $80.91M $1.914M
YoY Change
Accounts Payable $507.0K $6.362M $5.648M $5.679M $460.0K
YoY Change -92.03% 12.64% -0.55% 1134.57%
Accrued Expenses $3.638M $9.330M $3.141M $1.106M $137.0K
YoY Change -61.01% 197.04% 184.0% 707.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.145M $15.69M $8.789M $6.785M $597.0K
YoY Change -73.59% 78.54% 29.54% 1036.52%
Long-Term Debt $30.14M $29.44M $0.00 $0.00 $0.00
YoY Change 2.38%
Other Long-Term Liabilities $0.00 $2.000K $8.000K $15.00K $0.00
YoY Change -100.0% -75.0% -46.67%
Total Long-Term Liabilities $30.14M $29.44M $8.000K $15.00K $0.00
YoY Change 2.38% 367862.5% -46.67%
Total Liabilities $34.28M $45.13M $8.797M $6.800M $597.0K
YoY Change -24.04% 413.0% 29.37% 1039.03%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019
Basic Shares Outstanding 34.08M 23.27M 12.13M 791.8K
Diluted Shares Outstanding 34.08M 23.27M 12.13M 791.8K
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $34.159 Million

About Elevation Oncology, Inc.

Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company is headquartered in Boston, Massachusetts and currently employs 29 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.

Industry: Biological Products, (No Diagnostic Substances) Peers: 180 Life Sciences Corp. Spyre Therapeutics, Inc. Aptinyx Inc. Comera Life Sciences Holdings, Inc. GeoVax Labs, Inc. ORAGENICS INC Regulus Therapeutics Inc. TREVENA INC